

WenZhao Zhong

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6662866/wen-zhao-zhong-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

39
papers

717
citations

11
h-index

26
g-index

47
ext. papers

1,221
ext. citations

4.9
avg, IF

3.96
L-index

#	Paper	IF	Citations
39	Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIa (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. <i>Lancet Oncology</i> , 2018 , 19, 139-148	21.7	253
38	Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 -Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2235-2245	2.2	94
37	Acquired Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 4929-4937	12.9	50
36	Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIa (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial. <i>Journal of Clinical Oncology</i> , 2021 , 39, 713-722	2.2	44
35	Genomic Landscape and Immune Microenvironment Features of Preinvasive and Early Invasive Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2019 , 14, 1912-1923	8.9	41
34	The resistance mechanisms and treatment strategies for -mutant advanced non-small-cell lung cancer. <i>Oncotarget</i> , 2017 , 8, 71358-71370	3.3	34
33	Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma. <i>EBioMedicine</i> , 2020 , 60, 102990	8.8	29
32	Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art. <i>Cancer Communications</i> , 2021 , 41, 287-302	9.4	22
31	Lung cancer treatment disparities in China: a question in need of an answer. <i>Oncologist</i> , 2014 , 19, 1084-907	3.7	17
30	Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study. <i>Lung Cancer</i> , 2020 , 139, 118-123	5.9	17
29	Clinical efficacy of crizotinib in Chinese patients with ALK-positive non-small-cell lung cancer with brain metastases. <i>Journal of Thoracic Disease</i> , 2015 , 7, 1181-8	2.6	15
28	Genomic characteristics and drug screening among organoids derived from non-small cell lung cancer patients. <i>Thoracic Cancer</i> , 2020 , 11, 2279-2290	3.2	10
27	Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes. <i>Nature Communications</i> , 2021 , 12, 6450	17.4	9
26	Timing and Origins of Local and Distant Metastases in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1136-1148	8.9	9
25	Application of indocyanine green fluorescence for precision sublobar resection. <i>Thoracic Cancer</i> , 2019 , 10, 624-630	3.2	8
24	Randomized Trial of an Improved Drainage Strategy Versus Routine Chest Tube After Lung Wedge Resection. <i>Annals of Thoracic Surgery</i> , 2020 , 109, 1040-1046	2.7	6
23	Accidental invisible intrathoracic disseminated pT4-M1a: a distinct lung cancer with favorable prognosis. <i>Journal of Thoracic Disease</i> , 2015 , 7, 1205-12	2.6	6

22	Multiple Pulmonary Resections for Synchronous and Metachronous Lung Cancer at Two Chinese Centers. <i>Annals of Thoracic Surgery</i> , 2020 , 109, 856-863	2.7	6
21	Prophylactic air-extraction strategy after thoracoscopic wedge resection. <i>Thoracic Cancer</i> , 2018 , 9, 1406-1412	3.1	6
20	Wait-and-See Treatment Strategy Could be Considered for Lung Adenocarcinoma with Special Pleural Dissemination Lesions, and Low Genomic Instability Correlates with Better Survival. <i>Annals of Surgical Oncology</i> , 2020 , 27, 3808-3818	3.1	4
19	Recursive partitioning analysis of patients with oligometastatic non-small cell lung cancer: a retrospective study. <i>BMC Cancer</i> , 2019 , 19, 1051	4.8	4
18	Different dissecting orders of the pulmonary bronchus and vessels during right upper lobectomy are associated with surgical feasibility and postoperative recovery for lung cancer patients. <i>Chinese Journal of Cancer</i> , 2017 , 36, 53		4
17	Quantifying invasiveness of clinical stage IA lung adenocarcinoma with computed tomography texture features. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020 ,	1.5	4
16	Three-dimensional printed navigational template for localizing small pulmonary nodules: A case-controlled study. <i>Thoracic Cancer</i> , 2020 , 11, 2690-2697	3.2	3
15	Multomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy 2021 , 9,		3
14	Minimally invasive, multi-disciplinary approach for surgical management of a mediastinal congenital bronchogenic cyst in a 6-month-old infant. <i>Journal of Thoracic Disease</i> , 2017 , 9, E743-E747	2.6	2
13	Drainage tube hole suture improvement: Removal-free stitches. <i>Thoracic Cancer</i> , 2019 , 10, 1827-1833	3.2	2
12	MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors. <i>Experimental Hematology and Oncology</i> , 2021 , 10, 52	7.8	2
11	Real-World Survival Outcomes Based on Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study.. <i>JTO Clinical and Research Reports</i> , 2022 , 3, 100257	1.4	2
10	Precise resection of multiple pulmonary nodules using a three-dimensional reconstruction model: A case report. <i>Thoracic Cancer</i> , 2021 , 12, 970-973	3.2	2
9	A three-dimensional printing navigational template combined with mixed reality technique for localizing pulmonary nodules. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2021 , 32, 552-559	1.8	1
8	Impact of EGFR amplification on survival of patients with EGFR exon 20 insertion-positive non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2020 , 12, 5822-5832	2.6	1
7	Gene co-expression modules integrated with immunoscore predicts survival of non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2021 , 26, 100297	2	1
6	Adjuvant therapy for resected EGFR-mutant non-small-cell lung cancer - AuthorsTreply. <i>Lancet Oncology, The</i> , 2018 , 19, e127	21.7	0
5	Watershed analysis of the target pulmonary artery for real-time localization of non-palpable pulmonary nodules. <i>Translational Lung Cancer Research</i> , 2021 , 10, 1711-1719	4.4	0

4	Electromagnetic navigation bronchoscopic localization versus percutaneous CT-guided localization for thoracoscopic resection of small pulmonary nodules. <i>Thoracic Cancer</i> , 2021 , 12, 468-474	3.2	○
3	Identification of heritable rare variants associated with early-stage lung adenocarcinoma risk.. <i>Translational Lung Cancer Research</i> , 2022 , 11, 509-522	4.4	○
2	The superstars of precision medicine-EGFR inhibitors in adjuvant treatment of lung cancer. <i>Journal of Thoracic Disease</i> , 2019 , 11, E11-E13	2.6	
1	ASO Author Reflections: Lung Adenocarcinoma with Accidental Invisible Pleural Dissemination Lesions: Wait-and-See Strategy for Tumors with Indolent Biologic Characteristics. <i>Annals of Surgical Oncology</i> , 2020 , 27, 3819-3820	3.1	